The extra IFN-γ treatment, however, impaired the positive reaction to the binary treatment (pembrolizumab plus cetuximab) in five HNSCC samples, reducing it to only 7 out of 23 (Figure 2). Here, IFNG is linked to head and neck squamous cell carcinoma.